MAP2K7 and cancer: Recent work has focused on the next generation of MEK1/2 inhibitors, such as trametinib (GSK1120212) [20], which is a specific MEK/ERK inhibitor developed for cancer treatment [21] and prevents ERK phosphorylation in vivo [22].